Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

313.85
-1.4600-0.46%
Post-market: 313.850.00000.00%19:30 EDT
Volume:354.87K
Turnover:110.30M
Market Cap:18.98B
PE:34.07
High:314.43
Open:313.87
Low:308.53
Close:315.31
52wk High:330.75
52wk Low:263.00
Shares:60.49M
Float Shares:60.49M
Volume Ratio:1.52
T/O Rate:0.59%
Dividend:4.60
Dividend Rate:1.47%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.96
PE(LYR):7.56

Loading ...

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense

Reuters
·
Oct 06

Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie Inc. Fy2026 Shr View $14.02

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing

THOMSON REUTERS
·
Oct 06

Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer

MT Newswires Live
·
Oct 06

Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL

TIPRANKS
·
Oct 06

AbbVie Blood Cancer Drug Combo Cuts Risk of Progression or Death in Late-Stage Study

Reuters
·
Oct 06

Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study

TIPRANKS
·
Oct 06

Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL

Reuters
·
Oct 06

Genmab - Phase 3 Trial Shows 51% Reduction in Risk of Progression or Death in Dlbcl

THOMSON REUTERS
·
Oct 06

Genmab: Safety Profile of Epcoritamab When Administered in Combination with Standard of Care R-Chop was Generally Well Tolerated

THOMSON REUTERS
·
Oct 06

Genmab and Abbvie Announce Epcoritamab in Combination with R-Chop Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
Oct 06

Eli Lilly Stock (LLY) Gains on Regulatory Win for Experimental Cancer Drug

TIPRANKS
·
Oct 06

Sector Update: Healthcare Stocks Rise Monday Afternoon

MT Newswires Live
·
Oct 06

Exchange-Traded Funds Rise, US Equities Higher After Midday

MT Newswires Live
·
Oct 06

Mediobanca Steps Up Trading Activity in Listed Shares of Philogen

TIPRANKS
·
Oct 06

Emeis Executes Share Buyback as Mission-Driven Care Group Expands Role in Vulnerable Healthcare

TIPRANKS
·
Oct 06